EXTX: EXACT Therapeutics first half 2026 interim report

Oslo, Norway, 3 September 2026. EXACT Therapeutics AS (the "Company", Euronext
Growth ticker: EXTX), a clinical-stage precision medicine company, today
announces its interim report for the first half 2026. 

The interim report for the first half year 2026 is also available on the
company's website: www.exact-tx.com.

For further information, please contact: 
Per Walday 
CEO EXACT Therapeutics 
Email: per.walday@exact-tx.com

John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com

About EXACT Therapeutics: 
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are currently traded on Euronext Growth Oslo (EXTX). An
application for delisting of the shares has been approved by Oslo Stock
Exchange, and last day of trading is 9 October, 2026.  Further information may
be found here: www.exact-tx.com
ay\
be found here: www.exact-tx.com\